Current Status of Drug Therapy for Chronic Hepatitis B

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Date 2025 Jan 15

PMID 39811512

Authors

Chuang Jiang

Zhi-Hong Zhang

Jia-Xin Li

Affiliations

Soon will be listed here.

Abstract

In this editorial, we comment on the article by Meng . Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma. Prevention and treatment of HBV are key measures to reduce complications. At present, drug therapy can effectively control virus replication and slow disease progression, but completely eliminating the virus remains a challenge. Anti-HBV treatment is a long-term process, and there are many kinds of antiviral drugs with different mechanisms of action, it is essential to evaluate the safety and efficacy of these drugs to reduce side effects and improve patients' compliance. We will summarize the current status of CHB drug treatment, hoping to provide a reference for the selection of clinical antiviral drugs.

References

Hsu C, Su W, Lee C, Peng C, Chuang W, Kao J . Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018; 117(7):588-597. DOI: 10.1016/j.jfma.2017.12.007. View

Feld J, Wong D, Heathcote E . Endpoints of therapy in chronic hepatitis B. Hepatology. 2009; 49(5 Suppl):S96-S102. DOI: 10.1002/hep.22977. View

Lim S, Yang W, Ngu J, Chang J, Tan J, Ahmed T . Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2021; 20(2):e228-e250. DOI: 10.1016/j.cgh.2021.04.031. View

Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S . Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. J Gastroenterol. 2018; 54(2):182-193. DOI: 10.1007/s00535-018-1502-y. View

Su P, Su W, Hsu Y, Huang S, Yen H . Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ. 2021; 9:e12527. PMC: 8607928. DOI: 10.7717/peerj.12527. View

Li W, Deng R, Liu S, Wang K, Sun J . Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. Liver Int. 2020; 40(10):2316-2325. DOI: 10.1111/liv.14607. View

Fontana R . Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009; 49(5 Suppl):S185-95. DOI: 10.1002/hep.22885. View

Yao G, Zhu M, Cui Z, Wang B, Yao J, Zeng M . A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009; 10(2):131-7. DOI: 10.1111/j.1751-2980.2009.00375.x. View

Trepo C . A brief history of hepatitis milestones. Liver Int. 2013; 34 Suppl 1:29-37. DOI: 10.1111/liv.12409. View

10.

Giesler K, Liotta D . Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release. J Med Chem. 2016; 59(22):10244-10252. PMC: 5776677. DOI: 10.1021/acs.jmedchem.6b01292. View

11.

Lucifora J, Protzer U . Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol. 2016; 64(1 Suppl):S41-S48. DOI: 10.1016/j.jhep.2016.02.009. View

12.

Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A . Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2020; 56(2):168-180. DOI: 10.1007/s00535-020-01750-3. View

13.

Huang Y, Lee C, Yang S, Fu S, Chen Y, Wang T . Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol. 2016; 111(7):976-85. DOI: 10.1038/ajg.2016.179. View

14.

Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M . Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007; 133(5):1445-51. DOI: 10.1053/j.gastro.2007.08.079. View

15.

Stadler D, Kachele M, Jones A, Hess J, Urban C, Schneider J . Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep. 2021; 22(6):e49568. PMC: 8183418. DOI: 10.15252/embr.201949568. View

16.

Sun H, Tang Z, Wang L, Qin L, Ma Z, Ye Q . Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132(7):458-65. DOI: 10.1007/s00432-006-0091-y. View

17.

Mak L, Hoang J, Won Jun D, Chen C, Peng C, Yeh M . Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatol Int. 2021; 16(1):48-58. DOI: 10.1007/s12072-021-10271-x. View

18.

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6):1743-51. DOI: 10.1053/j.gastro.2006.09.020. View

19.

Murakami E, Wang T, Park Y, Hao J, Lepist E, Babusis D . Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015; 59(6):3563-9. PMC: 4432166. DOI: 10.1128/AAC.00128-15. View

20.

Lee M, Oh S, Lee H, Yeum T, Lee J, Yu S . Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat. 2013; 21(12):873-81. DOI: 10.1111/jvh.12217. View